Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Varsha Gandhi, PhD, on Ibrutinib

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Oct
26
Today In Oncology
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome
FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors
Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials
Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening
Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo